129 related articles for article (PubMed ID: 19682891)
1. Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989.
Schaapveld M; Visser O; Siesling S; Schaar CG; Zweegman S; Vellenga E
Eur J Cancer; 2010 Jan; 46(1):160-9. PubMed ID: 19682891
[TBL] [Abstract][Full Text] [Related]
2. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.
Kristinsson SY; Landgren O; Dickman PW; Derolf AR; Björkholm M
J Clin Oncol; 2007 May; 25(15):1993-9. PubMed ID: 17420512
[TBL] [Abstract][Full Text] [Related]
3. Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients - a large population-based study from 1990 to 2008.
van den Broek CB; Bastiaannet E; Dekker JW; Portielje JE; de Craen AJ; Elferink MA; van de Velde CJ; Liefers GJ; Kapiteijn E
Acta Oncol; 2013 Jun; 52(5):941-9. PubMed ID: 23145507
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
5. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
6. Survival of older patients with metastasised breast cancer lags behind despite evolving treatment strategies--a population-based study.
de Glas NA; Bastiaannet E; de Craen AJ; van de Velde CJ; Siesling S; Liefers GJ; Portielje JE
Eur J Cancer; 2015 Feb; 51(3):310-6. PubMed ID: 25559617
[TBL] [Abstract][Full Text] [Related]
7. Comparable survival for young rectal cancer patients, despite unfavourable morphology and more advanced-stage disease.
Orsini RG; Verhoeven RH; Lemmens VE; van Steenbergen LN; de Hingh IH; Nieuwenhuijzen GA; Rutten HJ
Eur J Cancer; 2015 Sep; 51(13):1675-82. PubMed ID: 26159248
[TBL] [Abstract][Full Text] [Related]
8. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010.
Issa DE; van de Schans SA; Chamuleau ME; Karim-Kos HE; Wondergem M; Huijgens PC; Coebergh JW; Zweegman S; Visser O
Haematologica; 2015 Apr; 100(4):525-33. PubMed ID: 25512643
[TBL] [Abstract][Full Text] [Related]
9. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
Ben Abid H; Meddeb B; Ben Abdallah M; Bel Hadj Ali Z; Hafsia R; Ben Lakhal R; Gouider E; Aissaoui L; Landoulsi I; ben Abdeladhim A; Hafsia A
Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
[TBL] [Abstract][Full Text] [Related]
11. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.
Liu L; Giusti F; Schaapveld M; Aleman B; Lugtenburg P; Meijnders P; Hutchings M; Lemmens V; Bogaerts J; Visser O
Br J Haematol; 2017 Jan; 176(1):65-75. PubMed ID: 27766636
[TBL] [Abstract][Full Text] [Related]
12. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
Klepin HD; Hurd DD
Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
14. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
[TBL] [Abstract][Full Text] [Related]
15. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
16. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
Jurczyszyn A; Nahi H; Avivi I; Gozzetti A; Niesvizky R; Yadlapati S; Jayabalan DS; Robak P; Pika T; Andersen KT; Rasche L; Mądry K; Woszczyk D; Raźny M; Usnarska-Zubkiewicz L; Knopińska-Posłuszny W; Wojciechowska M; Guzicka-Kazimierczak R; Joks M; Grosicki S; Ciepłuch H; Rymko M; Vesole DH; Castillo JJ
Br J Haematol; 2016 Dec; 175(5):884-891. PubMed ID: 27682187
[TBL] [Abstract][Full Text] [Related]
19. Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.
Johnsen HE; Klausen TW; Boegsted M; Lenhoff S; Gimsing P; Christiansen I; Gedde-Dahl T; Lindås R; Mellqvist UH;
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):290-6. PubMed ID: 20709667
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
